DrugBiological
Ocankitug clinical trials
Also written CM326.
- studies test it
- 13
- open now
- 5
- in phase 3
- 2
- first study started
- 2021
Keep track of what changes. Save the ocankitug studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- CM326
- 10
Studies by the year they started
13 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Keymed Biosciences Co.Ltd (8) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (3) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2)
Studies
Open first, then newest update. How each study uses ocankitug is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Comparative Pharmacokinetic Study of CM326 in Healthy SubjectsNot yet recruitingPhase 1CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT07560033Written as CM326(formulation 1)
- A Phase III Study of CM326 in Subjects With Moderate to Severe AsthmaRecruitingPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT07372287Written as CM326
- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal PolyposisNot yet recruitingPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT07420257Written as CM326 injection
- A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseRecruitingPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07418736Written as CM326 dose 1
- Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal PolyposisNot yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06372678Written as CM326
- A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 1/2Keymed Biosciences Co.LtdNCT05324137Written as CM326
- Study of CM326 Injection in Healthy SubjectsCompletedPhase 1Keymed Biosciences Co.LtdNCT05715333Written as CM326
- A Study of CM326 in Subjects With Moderate to Severe AsthmaStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05774340Written as CM326
- The Study of CM326 in Adult Subjects With Atopic DermatitisStatus unknownPhase 2Keymed Biosciences Co.LtdNCT05671445Written as CM326
- A Multiple Ascending Doses Study of CM326 Injection in Healthy SubjectsCompletedPhase 1Keymed Biosciences Co.LtdNCT05171348Written as CM326
- The Study of CM326 in Moderate-to-severe Atopic DermatitisStatus unknownPhase 2Keymed Biosciences Co.LtdNCT05671432Written as CM326
- Single Ascending Dose Study of CM326 in Healthy VolunteersCompletedPhase 1Keymed Biosciences Co.LtdNCT04842201Written as CM326
- The Study of CM326 in Patients With Moderate-to-severe Atopic DermatitisStatus unknownPhase 1/2Keymed Biosciences Co.LtdNCT05186922Written as CM326
Codes
What other systems call ocankitug · ClinicalTrials.gg INT015310
- UNII (FDA) 6Q8BN3S6ADOCANKITUGOne source FDA
- NCI Thesaurus C206953OcankitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6Q8BN3S6AD | OCANKITUG | One source FDA |
| NCI Thesaurus | C206953 | Ocankitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.